Jasper Therapeutics Stock Net Income
| JSPRW Stock | USD 0.14 0 2.14% |
Jasper Therapeutics fundamentals help investors to digest information that contributes to Jasper Therapeutics' financial success or failures. It also enables traders to predict the movement of Jasper Stock. The fundamental analysis module provides a way to measure Jasper Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Jasper Therapeutics stock.
| Last Reported | Projected for Next Year | ||
| Net Loss | -71.3 M | -67.7 M | |
| Net Loss | -71.3 M | -67.7 M | |
| Net Loss | -5.8 M | -6.1 M | |
| Net Loss | (5.56) | (5.84) | |
| Net Income Per E B T | 0.88 | 0.64 |
Jasper | Net Income |
Jasper Therapeutics Company Net Income Analysis
Jasper Therapeutics' Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Current Jasper Therapeutics Net Income | (71.27 M) |
Most of Jasper Therapeutics' fundamental indicators, such as Net Income, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Jasper Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Jasper Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Jasper Therapeutics is extremely important. It helps to project a fair market value of Jasper Stock properly, considering its historical fundamentals such as Net Income. Since Jasper Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Jasper Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Jasper Therapeutics' interrelated accounts and indicators.
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Based on the recorded statements, Jasper Therapeutics reported net income of (71.27 Million). This is 120.88% lower than that of the Biotechnology sector and 201.75% lower than that of the Health Care industry. The net income for all United States stocks is 112.48% higher than that of the company.
Jasper Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Jasper Therapeutics' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Jasper Therapeutics could also be used in its relative valuation, which is a method of valuing Jasper Therapeutics by comparing valuation metrics of similar companies.Jasper Therapeutics is currently under evaluation in net income category among its peers.
Jasper Fundamentals
| Return On Equity | -1.02 | ||||
| Return On Asset | -0.55 | ||||
| Number Of Shares Shorted | 18.04 K | ||||
| EBITDA | (76.24 M) | ||||
| Net Income | (71.27 M) | ||||
| Cash And Equivalents | 16.76 M | ||||
| Cash Per Share | 1.65 X | ||||
| Total Debt | 1.81 M | ||||
| Debt To Equity | 0.22 % | ||||
| Current Ratio | 1.96 X | ||||
| Book Value Per Share | 4.11 X | ||||
| Cash Flow From Operations | (62.6 M) | ||||
| Earnings Per Share | (3.84) X | ||||
| Number Of Employees | 64 | ||||
| Beta | 2.24 | ||||
| Total Asset | 79.9 M | ||||
| Retained Earnings | (240.87 M) | ||||
| Working Capital | 60.57 M | ||||
| Net Asset | 79.9 M |
About Jasper Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Jasper Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Jasper Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Jasper Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Jasper Stock Analysis
When running Jasper Therapeutics' price analysis, check to measure Jasper Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Jasper Therapeutics is operating at the current time. Most of Jasper Therapeutics' value examination focuses on studying past and present price action to predict the probability of Jasper Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Jasper Therapeutics' price. Additionally, you may evaluate how the addition of Jasper Therapeutics to your portfolios can decrease your overall portfolio volatility.